AEGIRBIO
Aegirbio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform.
AEGIRBIO
Industry:
Biotechnology
Founded:
2019-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.aegirbio.com
Total Employee:
1+
Status:
Active
Contact:
+1 858 203 1169
Total Funding:
1.91 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Nginx Google Cloud YouTube COVID-19 Ubuntu Google Cloud CDN
Current Advisors List
Current Employees Featured
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-09-08 | Viraspec | Viraspec acquired by Aegirbio | N/A |
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - Aegirbio
Key Employee Changes
| Date | New article |
|---|---|
| 2023-10-09 | AegirBio promotes Dr. Vasiliki Fragkou to Chief Operating Officer from November 1, 2023. |
Official Site Inspections
http://www.aegirbio.com Semrush global rank: 11.43 M Semrush visits lastest month: 162
- Host name: a67c48129651a0940.awsglobalaccelerator.com
- IP address: 13.248.213.45
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Aegirbio"
AegirBio AB changes name to Magnasense AB
Mar 5, 2025 Today, AegirBio AB announces that the company’s name has officially been changed to Magnasense AB in the Swedish Companies Register. This registration follows that …See details»
Uppdatering om organisation i AegirBio - Magnasense
AegirBio är ett svenskt diagnostikföretag som bildades för att via sin unika patenterade teknologiplattform erbjuda tester för att övervaka och optimera doseringen av biologiska …See details»
The next step is taken for Aegirbio, a pre-IPO based on a value of …
Feb 19, 2025 Aegirbio's test for the follow-up of treatment with Tysabri, a drug used to treat patients with Multiple Sclerosis MS, will now be set up in the United States. The company's …See details»
Magnasense - Crunchbase Company Profile & Funding
Magnasense is basing its operations on laboratory-developed tests and technologies for patient follow-up during biological drug treatment; quantitative near-patient tests for routine control in …See details»
AegirBio Company Profile - Office Locations, Competitors ... - Craft
AegirBio kr92 k in annual revenue in FY 2023. See insights on AegirBio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
AegirBio AB changes name to Magnasense AB | Placera
Jul 8, 2024 Consequently, the board of AegirBio proposed, pursuant to the authority granted by the annual general meeting 2024, Magnasense AB as the new company name which was …See details»
AegirBio AB (publ): Shareholders Board Members Managers and …
Apr 30, 2020 Magnasense AB, formerly AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and …See details»
AegirBio announces strategic name change to MagnOral AB
Mar 3, 2025 Lund, 4 May 2024 – AegirBio AB, a pioneer in magnetic test strip technology and saliva diagnostics, announces that it will change its name to MagnOral AB, pending approval …See details»
Magnasense 2025 Company Profile: Stock Performance
Description AegirBio AB is a Swedish diagnostic company, specializes in developing a home testing platform for oral health, therapeutic drug monitoring and infectious diseases. The …See details»
AegirBio_Q4 Draft (240328 v8) ENG - files.wewoosh.com
AegirBio AB has received a phase 1 award from the National Institutes of Health (NIH) for an accessibility project (RADx). The award grants AegirBio MUSD 1.2 from NIH, of which …See details»
AegirBio AB (AEGIR) | Investor Relations Data & Reports
Browse AegirBio AB's (AEGIR) investor relations materials including 2024 annual reports, financial statements, ESG data, and company filings.See details»
Annual Report 2021 - filel.mywoosh.app
Aegirbio is a biotechnology company founded with the business concept of developing and commercializing tests to monitor the dosing of biological drugs to ensure that the right dosing …See details»
AegirBio AB (publ): Shareholders Board Members Managers and …
AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. The Company offers …See details»
Aegirbio creates the multi-diagnostic company of the future – …
Jan 28, 2021 The Board of Directors of AegirBio AB (publ) has today resolved to acquire LifeAssays AB and Abreos Bioscience. Through these acquisitions, Aegirbio becomes a …See details»
HEALTH CHECK. PRECISION. SIMPLICITY.
AegirBio, established in 2019, is a Swedish diagnostics company that develops and commercializes diagnostic tests, with a key focus on monitoring and optimizing the dosing of …See details»
AegirBio_Q3-Draft-231027 ENG - Wewoosh
AegirBio AB has received a phase 1 award from the National Institutes of Health (NIH) for an accessibility project (RADx). The award grants AegirBio MUSD 1.2 from NIH, of which …See details»
Aegirbio - Overview, News & Competitors | ZoomInfo.com
Aegirbio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform.See details»
Company Updates - Magnasense
May 2, 2024 Brand Change Announcement: AegirBio AB has officially changed its name to Magnasense AB. The new website, www.magnasense.com, launched on 9 July 2024, with …See details»
The next step is taken for Aegirbio AB, LifeAssays and Abreos ...
Jan 17, 2020 Aegirbio's test for the follow-up of treatment with Tysabri, a drug used to treat patients with Multiple Sclerosis MS, will now be set up in the United States. The company's …See details»
AegirBio UK facility ISO 13485 compliant - Magnasense
Mar 3, 2025 Aegirbio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform.See details»